Farallon Capital Management LLC Sells 234,200 Shares of Cencora, Inc. (NYSE:COR)

Farallon Capital Management LLC reduced its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 99.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,000 shares of the company's stock after selling 234,200 shares during the quarter. Farallon Capital Management LLC's holdings in Cencora were worth $225,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of COR. JFS Wealth Advisors LLC boosted its stake in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the last quarter. Banque Transatlantique SA acquired a new position in Cencora during the fourth quarter worth about $29,000. SBI Securities Co. Ltd. purchased a new stake in Cencora during the 4th quarter valued at about $30,000. Kentucky Trust Co purchased a new stake in Cencora during the 4th quarter valued at about $33,000. Finally, Householder Group Estate & Retirement Specialist LLC grew its stake in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on COR shares. Robert W. Baird boosted their price target on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday. UBS Group lifted their target price on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Morgan Stanley set a $288.00 price target on shares of Cencora in a research note on Tuesday, April 15th. Bank of America raised their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Finally, Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus target price of $301.18.

Cencora Trading Down 0.2%

COR traded down $0.65 on Friday, reaching $283.12. 2,786,039 shares of the company's stock were exchanged, compared to its average volume of 1,526,366. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $309.35. The company's 50 day moving average is $276.48 and its 200-day moving average is $253.57. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a market cap of $54.90 billion, a price-to-earnings ratio of 40.27, a PEG ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $3.80 earnings per share. Equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.78%. The ex-dividend date is Friday, May 16th. Cencora's dividend payout ratio is currently 25.52%.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. This represents a 24.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,223 shares of company stock worth $13,580,967 over the last ninety days. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.